{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-039308","form_type":"8-K","ticker":"SNWV","cik":"0001417663","company_name":"SANUWAVE Health, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.859489+00:00","generated_at":"2026-06-11T14:02:59.473443+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SANUWAVE Q2 revenue $4.7M (+20% YoY); net loss $7.3M; guides Q3 growth 15-25%","bullets":["Q2 revenue $4.7M (+20% YoY) within 15-25% guidance; H1 revenue $8.5M (+19%).","Gross margin improved to 74% from 72%; operating income $0.9M with $1.25M one-time expense reversal.","Net loss $7.3M vs net income $1.6M in Q2 2022 due to non-cash derivative liability losses.","Q3 2023 revenue growth guidance 15-25% YoY; inventory constraints expected to ease in Q4.","Recent: CEO Morgan Frank (May), President Andrew Walko (July), $3M asset-backed notes issued."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-039308","json":"https://secwatch.observer/filing/0001140361-23-039308.json","markdown":"https://secwatch.observer/filing/0001140361-23-039308.md","text":"https://secwatch.observer/filing/0001140361-23-039308.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417663/000114036123039308/0001140361-23-039308-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417663/000114036123039308/brhc20057422_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:02:59.473443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f72d75980cf055cbfe43b5066fbd86b200035c21","claim":"SANUWAVE Health, Inc. reported second quarter ended June 30, 2023 results: revenue $4.7 million, net income $7.3 million. Guidance reaffirmed.","evidence_excerpt":"wound care products, today announced its 2nd quarter 2023 results. For the three months ended June 30, 2023: ■ Revenue for the three months ended June 30, 2023 totaled $4.7 million, an increase of 20%, as compared to $3.9 million for the same period of 2022. This growth falls within the previously provided guidance range of 15-25% for Q2 2023. Revenue for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417663/000114036123039308/0001140361-23-039308-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$4.7 million"},{"label":"Net income","value":"$7.3 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}